Phase II study of methyl-glyoxal bis-guanylhydrazone (NSC 3296) in advanced ovarian cancer.

Abstract

Thirty-nine patients received 600 mg/m2 OF MGBG intravenously every week for the treatment of advanced refractory ovarian cancer. Twenty-seven of these received adequate trials, and only two had partial remissions lasting 3 1/2 and 4 months each. Toxicity was substantial, with severe hematologic toxicity in 26%, diarrhea in 22% (severe in 7%), skin rash in 26% (severe in 7%), and vomiting in 70% (severe in 11%). Fatigue, facial paresthesias, and flushing during drug administration were frequent. It appears that MGBG in this dose and schedule has little activity against advanced ovarian cancer.

• Authors: S E Vogl, M Pagano, J Horton
• Journal: American journal of clinical oncology (Am J Clin Oncol) Vol. 7 Issue 6 Pg. 733-6 (Dec 1984) ISSN: 0277-3732 [Print] United States
• PMID: 6528867 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Guanidines
• Mitoguazone

Topics

• Blood (drug effects)
• Drug Evaluation
• Fatigue (chemically induced)
• Female
• Guanidines (therapeutic use)
• Humans
• Mitoguazone (adverse effects, therapeutic use)
• Ovarian Neoplasms (drug therapy)
• Vomiting (chemically induced)